Drug Stock Set to Crush Shorts After Data

Analysts are already bullish on AKBA stock

Mar 12, 2019 at 9:02 AM
facebook X logo linkedin

The shares of Akebia Therapeutics Inc (NASDAQ:AKBA) have shot up 23.4% in electronic trading, after the Massachusetts-based firm reported positive data from a pair of late-stage studies for vadadustat -- used to treat patients with anemia due to chronic kidney disease. The studies were part of a collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC), which plans to apply for vadadustat marketing approval in Japan later this year.

Heading into today's trading, AKBA shares were down 48% year-over-year. More recently, the stock has come off its late-December low, adding 32.7% year-to-date through last night's close at $7.34. Should today's pre-market price action pan out, the equity could test its 200-day moving average -- a trendline that contained a mid-December breakout attempt, and hasn't been toppled on a daily closing basis since Jan. 29, 2018.

Analysts have yet to weigh in after the drug data, though sentiment from this bunch is currently bullish. While five of six covering brokerages maintain a "buy" or better rating, the average 12-month price target of $17.29 is a stiff 135.6% premium to Monday's settlement.

Short sellers, meanwhile, could be pressured to cover -- which would likely strengthen tailwinds for Akebia Therapeutics stock. Short interest rose 14.3% in the two most recent reporting periods to 6.97 million shares. This represents a healthy 6.5% of AKBA's total  available float, or 8.8 times the average daily pace of trading.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI